<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05027906</url>
  </required_header>
  <id_info>
    <org_study_id>AT-1501-K102</org_study_id>
    <nct_id>NCT05027906</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant</brief_title>
  <official_title>A Phase 1b, Multicenter, Open Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eledon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eledon Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, PK, and efficacy of AT 1501 in patients undergoing&#xD;
      kidney transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the safety, PK, and efficacy of AT 1501 in patients undergoing&#xD;
      kidney transplantation. Up to 12 de novo kidney transplant recipients will receive AT-1501 in&#xD;
      combination with rATG induction with CS, and mycophenolate as maintenance therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Phase 1b, open label, single-arm study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>None ( Open Label)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Incidences</measure>
    <time_frame>Through study completion, an average up to 20 months</time_frame>
    <description>Incidence of treatment emergent adverse events (TEAEs), serious adverse events (SAEs), and Adverse Events of Special Interest (AEoSI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic- PK profile</measure>
    <time_frame>Day 1 and at steady state Month 3</time_frame>
    <description>PK profile of the first dose of AT 1501 and at steady state Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (Ct), calculated using the linear trapezoidal method (AUC0-t)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic- Area under the plasma concentration</measure>
    <time_frame>Day 1 and at steady state Month 3</time_frame>
    <description>Area under the plasma concentration versus time curve from time 0 extrapolated to infinity, calculated using the linear trapezoidal method (AUC0-inf)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic- Cmax</measure>
    <time_frame>Day 1 and at steady state Month 3</time_frame>
    <description>Maximum observed plasma concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic- Tmax</measure>
    <time_frame>Day 1 and at steady state Month 3</time_frame>
    <description>Time to reach maximum observed plasma concentration (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic- Ke</measure>
    <time_frame>Day 1 and at steady state Month 3</time_frame>
    <description>Terminal elimination rate constant (Ke)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic- (t1/2)</measure>
    <time_frame>Day 1 and at steady state Month 3</time_frame>
    <description>Terminal phase half-life (t1/2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic- CL</measure>
    <time_frame>Day 1 and at steady state Month 3</time_frame>
    <description>Clearance (CL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic- (Vdss)</measure>
    <time_frame>Day 1 and at steady state Month 3</time_frame>
    <description>Volume of distribution at steady state (Vdss)</description>
  </primary_outcome>
  <other_outcome>
    <measure>Incidence of BPAR</measure>
    <time_frame>6 and 12 months post-transplant</time_frame>
    <description>Incidence of BPAR (T cell-mediated rejection [TCMR] Banff Grade ≥ 1A and antibody mediated rejection [AMR])</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in eGFR</measure>
    <time_frame>Month 1 to Month 3, 6, 12, and 15 post-transplant</time_frame>
    <description>Changes in eGFR</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of composite endpoint</measure>
    <time_frame>12 months post-transplant</time_frame>
    <description>Rate of composite endpoint (graft failure, BPAR, or death)</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of DSA</measure>
    <time_frame>1, 3, 6, 9, 12, and 15 months post-transplant and at the time of for cause biopsies</time_frame>
    <description>DSA</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of donor derived cell free DNA (dd-cfDNA)</measure>
    <time_frame>3, 6, 9, 12, and 15 months post-transplant and at the time of for cause biopsies</time_frame>
    <description>(dd-cfDNA)</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacodynamic Studies</measure>
    <time_frame>Day 0 and Months 3, 6, 9, 12, and 15 post-transplant and at the time of for-cause biopsies</time_frame>
    <description>CD40L receptor occupancy and gene expression studies</description>
  </other_outcome>
  <other_outcome>
    <measure>Trough levels of AT-1501</measure>
    <time_frame>Days 7, 14, 21 and Months 1, 3, 6, 9, 12, and 15 post-transplant</time_frame>
    <description>Trough levels</description>
  </other_outcome>
  <other_outcome>
    <measure>Anti-AT-1501 antibody studies</measure>
    <time_frame>Months 1, 3, 6, 12, and 15 post-transplant</time_frame>
    <description>Incidence of anti- AT-1501 antibodies</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Kidney Transplant</condition>
  <arm_group>
    <arm_group_label>AT-1501 Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AT-1501 monoclonal antibody targeting CD40L given as an IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT-1501</intervention_name>
    <description>Investigative Arm</description>
    <arm_group_label>AT-1501 Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female ≥ 18 years of age&#xD;
&#xD;
          2. Recipient of their first kidney transplant from a living or deceased donor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Induction therapy, other than study assigned rATG, planned as part of initial&#xD;
             immunosuppressive regimen&#xD;
&#xD;
          2. Currently treated with any systemic immunosuppressive regimen, including immunologic&#xD;
             biologic therapies, with the exception of 5 mg prednisone or equivalent daily;&#xD;
&#xD;
          3. Previous treatment with AT 1501 or any other anti CD40LG therapy&#xD;
&#xD;
          4. The patient has previously received a bone marrow transplant or any other solid organ&#xD;
             transplant, including a kidney, or will be undergoing a multi organ or dual kidney&#xD;
             transplant&#xD;
&#xD;
          5. Will receive a kidney with an anticipated cold ischemia time of &gt; 30 hours;&#xD;
&#xD;
          6. Will receive a kidney from a donor that meets any of the following:&#xD;
&#xD;
             • Donation after Cardiac Death (DCD) criteria; or&#xD;
&#xD;
             Extended Criteria Donor (ECD) criteria, defined as:&#xD;
&#xD;
               -  Is blood group (ABO) incompatible; or&#xD;
&#xD;
               -  Age ≥ 60 years; or&#xD;
&#xD;
               -  Age 50-59 years with any 2 of the following criteria&#xD;
&#xD;
               -  Death due to cerebrovascular accident&#xD;
&#xD;
               -  History of hypertension&#xD;
&#xD;
               -  Terminal creatinine ≥ 133 μmol/L&#xD;
&#xD;
          7. Human leukocyte antigen identical (two haplotype match or zero HLA mismatch) donor&#xD;
&#xD;
          8. Medical conditions that require chronic use of systemic steroids at a dose higher than&#xD;
             5 mg prednisone or equivalent per day&#xD;
&#xD;
          9. History of a TE event, known hypercoagulable state, or condition requiring long term&#xD;
             anticoagulation:&#xD;
&#xD;
               1. Patients with a history of clotted venous access not requiring long term&#xD;
                  anticoagulation may be included at the Investigator's discretion if have no other&#xD;
                  history of TE events or known hypercoagulable state&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff Bornstein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Eledon Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lois Kelly</last_name>
    <phone>949-238-8090</phone>
    <email>lkelly@eledon.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 19, 2021</study_first_submitted>
  <study_first_submitted_qc>August 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney Transplant</keyword>
  <keyword>Renal Allograft Rejection</keyword>
  <keyword>Prophylaxis</keyword>
  <keyword>AT-1501</keyword>
  <keyword>CD40L inhibitor</keyword>
  <keyword>Humanized blocking antibody to CD40L</keyword>
  <keyword>Monoclonal Antibody</keyword>
  <keyword>Renal</keyword>
  <keyword>Transplant</keyword>
  <keyword>CKD</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

